Company profile: Xenetic Biosciences
1.1 - Company Overview
Company description
- Provider of biopharmaceutical drugs, cancer therapies and vaccines, centered on a DNase I oncology platform and NETs-targeting approaches for pancreatic and other solid tumors; collaborates with Volition on NETs-targeted adoptive cell therapies; holds sublicenses for PolyXen technology for blood/bleeding disorders and DNase enzyme-based cancer treatments; contracts cGMP manufacturing of recombinant Human DNase I.
Products and services
- DNase I Oncology Platform: Produces an enzyme-based platform aimed at improving cancer therapies by addressing multiple oncology indications, including pancreatic cancer and other solid tumors
- NETs Targeting: Develops a mechanism-specific strategy to target Neutrophil Extracellular Traps (NETs) involved in cancer progression and resistance to treatments across oncology indications
- Partnership with Volition: Orchestrates an adoptive-cell-based collaboration to develop NETs-targeted adoptive cell therapies for cancer treatment, specifically focused on targeting NETs within oncology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xenetic Biosciences
Sunovion
HQ: United States
Website
- Description: Provider of therapeutic products discovered, developed and commercialized for central nervous system and respiratory disorders and other illnesses. Portfolio includes Latuda for schizophrenia and bipolar depression; Aptiom for partial-onset seizures; Gemtesa/vibegron for overactive bladder; Myfembree for heavy menstrual bleeding due to uterine fibroids; Orgovyx for advanced prostate cancer; LUNESTA; and XOPENEX.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sunovion company profile →
Regeneron
HQ: United States
Website
- Description: Provider of innovative medicines, including EYLEA for eye diseases (age-related macular degeneration, diabetic retinopathy); Dupixent for atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis; REGEN-COV for COVID-19; Libtayo for certain skin cancers and non-small cell lung cancer; Praluent to lower LDL cholesterol; and Kevzara for rheumatoid arthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regeneron company profile →
Manhattan Pharma
HQ: United States
Website
- Description: Provider of specialty healthcare product development and commercialization focused on innovative treatments for underserved patient populations, advancing a portfolio of product candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Manhattan Pharma company profile →
Adnexus Therapeutics
HQ: United States
Website
- Description: Provider of discovery and development of Adnectins, a novel proprietary class of targeted biologics designed to block or stimulate therapeutic targets to fight diseases across a broad range of therapeutic areas; operates as a Bristol-Myers Squibb R&D company in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adnexus Therapeutics company profile →
Cyclenium Pharma
HQ: Canada
Website
- Description: Provider of next-generation macrocyclic drug discovery technology (CMRT) and the QUEST library of small-molecule macrocycles to identify novel therapeutics for difficult disease targets. Offers collaborative drug discovery, out-licensing of advanced leads (e.g., anti-flaviviral agents, opioid receptor agonists), and in-licensing opportunities in oncology and anti-infectives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclenium Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xenetic Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xenetic Biosciences
2.2 - Growth funds investing in similar companies to Xenetic Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xenetic Biosciences
4.2 - Public trading comparable groups for Xenetic Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →